{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Charton E"],"funding":["Celgene","Institut National Du Cancer"],"pagination":["5079-5088"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6718524"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(11)"],"pubmed_abstract":["Background
The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first-line therapy combining nab-paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic cancer. Results of progression-free survival at 4 months (primary endpoint) were in favor of the sLV5FU2 group. This paper presents health-related quality of life (HRQoL) data as a secondary endpoint.Methods
HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and at each chemotherapy cycle until the end of treatment. The HRQoL deterioration-free survival (QFS) was used as a modality of longitudinal analysis. QFS was defined as the time between randomization and the first definit"],"journal":["Cancer medicine"],"pubmed_title":["Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial."],"pmcid":["PMC6718524"],"funding_grant_id":["INCA 11862"],"pubmed_authors":["Desrame J","Seitz JF","Cohen R","Aparicio T","Taieb J","Anota A","Dauba J","Volet J","Hammel P","Chibaudel B","Louvet C","Debourdeau P","Bonnetain F","Guerin-Meyer V","Bachet JB","Charton E","Lecomte T","Tournigand C"],"additional_accession":[]},"is_claimable":false,"name":"Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.","description":"Background
The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first-line therapy combining nab-paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic cancer. Results of progression-free survival at 4 months (primary endpoint) were in favor of the sLV5FU2 group. This paper presents health-related quality of life (HRQoL) data as a secondary endpoint.Methods
HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and at each chemotherapy cycle until the end of treatment. The HRQoL deterioration-free survival (QFS) was used as a modality of longitudinal analysis. QFS was defined as the time between randomization and the first definit","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2026-05-01T19:37:58.921Z","creation":"2019-09-12T07:04:44Z"},"accession":"S-EPMC6718524","cross_references":{"pubmed":["31314957"],"doi":["10.1002/cam4.2311"]}}